Heron Therapeutics (HRTX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to 0.06.
- Heron Therapeutics' Equity Ratio rose 13299.71% to 0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06, marking a year-over-year increase of 13299.71%. This contributed to the annual value of 0.14 for FY2024, which is 546.86% up from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' Equity Ratio is 0.06, which was up 13299.71% from 0.12 recorded in Q2 2025.
- Heron Therapeutics' 5-year Equity Ratio high stood at 0.63 for Q1 2021, and its period low was 0.2 during Q2 2023.
- Over the past 5 years, Heron Therapeutics' median Equity Ratio value was 0.09 (recorded in 2022), while the average stood at 0.02.
- Per our database at Business Quant, Heron Therapeutics' Equity Ratio plummeted by 38231.71% in 2023 and then soared by 13299.71% in 2025.
- Quarter analysis of 5 years shows Heron Therapeutics' Equity Ratio stood at 0.25 in 2021, then crashed by 78.69% to 0.05 in 2022, then tumbled by 382.32% to 0.15 in 2023, then grew by 5.47% to 0.14 in 2024, then skyrocketed by 141.43% to 0.06 in 2025.
- Its Equity Ratio stands at 0.06 for Q3 2025, versus 0.12 for Q2 2025 and 0.12 for Q1 2025.